Ibandroninezuur Genthon (Ibandronic Acid)

Ibandronic acid binds to hydroxyapatite on bone surfaces. When osteoclasts attach to this drug‑coated bone, the compound is taken up, disrupting the mevalonate pathway, leading to loss of essential prenylated proteins and causing osteoclast apoptosis. This reduces bone resorption and stabilises bone density.

The specific dose and dosing schedule of Ibandroninezuur Genthon are determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Patients should follow the exact instructions provided by their healthcare professional.

Safety data for ibandronic acid in pregnancy and lactation are limited. The product is generally not recommended for use in pregnant or breastfeeding women unless the potential benefit outweighs the potential risk, and this decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Ibandroninezuur Genthon, like other bisphosphonates (e.g., alendronate, risedronate), inhibits osteoclast‑mediated bone resorption. Ibandronate is often administered once monthly, which can improve adherence compared with weekly or daily regimens of some alternatives. Efficacy and safety profiles are broadly comparable, though individual patient factors may guide the choice of agent.

Store Ibandroninezuur Genthon at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight and heat sources to maintain stability and potency.

The medication is taken orally as a tablet with a full glass of plain water, preferably on an empty stomach. Patients should remain upright for at least 30 minutes after dosing and avoid eating, drinking, or taking other medications during that time to reduce the risk of esophageal irritation.

Serious adverse events, though rare, include osteonecrosis of the jaw, atypical femoral fractures, severe esophagitis, and acute renal impairment. Patients should be monitored for persistent jaw pain, unusual thigh pain, or signs of kidney dysfunction and report these promptly to their healthcare provider.

Ibandroninezuur Genthon is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), active esophageal disorders, hypersensitivity to ibandronic acid or any excipients, and in women who are pregnant or breastfeeding unless clearly indicated by a physician.